(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072602 A2

(51) International Patent Classification[7]: C07K

(21) International Application Number: PCT/US02/06676

(22) International Filing Date: 5 March 2002 (05.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/274,308 8 March 2001 (08.03.2001) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/274,308 (CON)
Filed on 8 March 2001 (08.03.2001)

(71) Applicant *(for all designated States except US)*: **THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND** [US/US]; 1430 Tulane Avenue, New Orleans, LA 70112 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **COY, David, H.** [US/US]; 1529 Fourth Street, New Orleans, LA 70130 (US). **MURPHY, William, A.** [US/US]; 1242 St. Christopher Drive, Slidell, LA 70460 (US). **RAJESWARAN, Walajapet, G.** [IN/US]; 2300 Edenborn Avenue, Metairie, LA 70001 (US).


(74) Agent: **CLARK, Paul, T.**; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: SOMATOSTATIN ANTAGONISTS



A^1-cyclo{D-Cys-A^2-D-Trp-A^3-A^4-Cys}-A^5-Y^1 (I)

(57) Abstract: The present invention is directed to a somatostatin antagonist according to formula (I), wherein A^1 is an optionally substituted aromatic ∝-amino acid; A^2 is an optionally substituted aromatic ∝-amino acid; A^3 is Dab, Dap, Lys or Orn; A^4 is β-Hydroxyvaline, Ser, Hser, or Thr; A^5 is an optionally substituted D- or L-aromatic -amino acid; and Y^1 is OH, NH_2 or NHR^1, where R^1 is (C_{1-6})alkyl; wherein each said optionally substituted aromatic -amino acid is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, NO_2, OH, CN, (C_{1-6})alkyl, (c_{2-6})alkenyl, (c_{2-6})alkynyl, (C_{1-6})alkoxy, Bzl, O-Bzl, and NR^9R^{10}, where R^9 ad R^{10} each is independently H, O, or (C_{1-6})alkyl; and wherein the amine nitrogen of each of amide peptide bond and the amino group of A^1 of formula (I) is optionally substituted with a methyl group, provided that there is at least one said methyl group; or a pharmaceutically acceptable salt thereof, and to uses thereof.

WO 02/072602 A2



European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.